Human Microbiome-based Drugs and Diagnostics: Global Markets

Report Highlights

The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.

Report Includes

• 55 data tables and 51 additional tables
• Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region
• Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
• Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments
• An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development
• Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
• An analysis of the key patent grants and recently published patents
• Analysis of the industry structure and value chain, and the competitive landscape, including companies’ market shares, strategic alliances, M&A activity, venture fundings and investment outlook
• Profiles of the leading companies, including Ferring Pharmaceuticals, Nestlé Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc.

Report Scope

The report analyzes the global market for human microbiome-based drugs and diagnostics and market trends. It includes global revenues for the base year 2024, estimated data for 2025 and the compound annual growth rates (CAGRs) for forecast period of 2025 to 2030. The market is segmented by type, application, end user and region. The microbiome-based drug segment is further segmented by route of administration: oral or rectal. Microbiome-based diagnostics are segmented based on product type into instruments, and reagents and kits. End-user segments include hospitals and clinics, pharmaceutical companies and research institutes. Applications include metabolic, gastrointestinal (GI) and infectious diseases, cancer and others. The regions covered include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA). The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) developments.

Human microbiome-based products that are intended for wellness or as dietary supplements are outside the scope of the report, as are nonstandardized fecal microbiota transplantation (FMT) procedures. Microbiome-based diagnostics include only products that claim to detect or screen for any disease or condition.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.